# Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

> **NCT06817720** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** olverembatinib

## Key facts

- **NCT ID:** NCT06817720
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-13
- **Primary completion:** 2027-03-07
- **Final completion:** 2027-03-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06817720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06817720, "Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06817720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*